Fair Value Calculator Fair Value Calculator
EN DE

Clinical Laserthermia Systems AB (CLS-B) Fair Value & Analysis

Healthcare · SE · Market cap 106M SEK

CL Clinical Laserthermia Systems AB CLS-B · ST
Pricekr 3.19
Fair Valuekr 0.8840
Upside-72.3%
Quality23/100
Watch Clinical Laserthermia Systems AB for free, get notified when fair value or trend changes. Watch for free
Evidence: Low Range kr 0.5780 – kr 1.11 📤 Share as image

Fair value as of: Jul 12, 2026

From 1 valuation models · updated 9 days ago

Share price −10.8% over the past month.

Price vs Fair Value (12 months)

kr 11.82 kr 3.15 Fair Value kr 0.8840 Jul 2025 Jul 2026

12‑month range kr 3.15 – kr 11.82 · fair‑value band kr 0.5780 – kr 1.11 · the kr 3.19 price screens above the kr 0.8840 fair value. As of Jul 12, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Clinical Laserthermia Systems AB (CLS-B) currently trades at kr 3.19, while our model-based Fair Value estimate is kr 0.8840, implying the stock looks roughly 72.3% overvalued today. We read business quality at 23/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at 14.3M SEK. Revenue declined 71.6% year over year. It earns a return on equity of -53.2%. The balance sheet holds a net cash position of 21.5M SEK. Fundamentals as of Jul 12, 2026

Our scenario range runs from kr 0.5780 (bear case) to kr 1.11 (bull case); at kr 3.19, the current price sits above that range. The share trades about 76% below its 52-week high and 23% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -72%, CLS-B screens richer than that median.

Key figures & financial health

Revenue (TTM) 14.3M SEK
Revenue growth (YoY) -71.6%
Net margin -237%
Return on equity -53.2%
Free cash flow −35.9M SEK FY2025
Operating margin -757%
More key figures
EPS (TTM) kr -1.10
Net cash 21.5M SEK FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.

About the company

Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control treatment. In addition, it offers various gauge laser applicators and introducers, as well as provides temperature and treatment monitoring devices. The company has a strategic partnership with ClearPoint Neuro Inc. for the development of ClearPoint Prism, a Neuro Laser Therapy System. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Clinical Laserthermia Systems AB reported revenue of kr 17.5M in FY2025 versus kr 2.2M in FY2021, a compound +67.1%/yr. Reported net income was −kr 41.6M in FY2025.

Revenue +67.1%/yr
FY21 kr 2.2M
FY22 kr 6.3M
FY23 kr 8.3M
FY24 kr 18.8M
FY25 kr 17.5M
Net income
FY21 −kr 63.6M
FY22 −kr 70.7M
FY23 −kr 79.8M
FY24 −kr 47.6M
FY25 −kr 41.6M

Is CLS-B fairly valued? → Check now

📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog, it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Clinical Laserthermia Systems AB Fair Value". https://www.fairvalue-calculator.com/stock/CLS-B

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $86.97 $69.36 -20%
Stryker Corporation SYK $305.66 $187.83 -39%
Medtronic plc MDTC34 R$210.63 R$24.08 -89%
Boston Scientific Corporation B1SX34 R$247.01 R$234.82 -5%
Edwards Lifesciences Corporation EWL €74.64 €31.98 -57%
Siemens Healthineers AG SEMHF $40.29 $47.96 +19%
DexCom, Inc DXCM $74.77 $53.93 -28%
GE HealthCare Technologies Inc GEHC $61.99 $48.34 -22%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥141.85 ¥147.63 +4%
Koninklijke Philips N.V PHG $26.98 $10.24 -62%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Clinical Laserthermia Systems AB (CLS-B) undervalued?
As of Jul 12, 2026, our model estimates a fair value of kr 0.8840 versus a price of kr 3.19, about −72% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CLS-B?
Our model-based fair value for Clinical Laserthermia Systems AB is kr 0.8840 (as of Jul 12, 2026), built from audited fundamentals. The current price is kr 3.19.
What is the quality score of CLS-B?
Clinical Laserthermia Systems AB has a Quality Score of 23/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Clinical Laserthermia Systems AB (CLS-B)?
Clinical Laserthermia Systems AB reported trailing-twelve-month revenue of about 14.3M SEK (latest available figure, as of Jul 12, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Unlock the full Clinical Laserthermia Systems AB analysis, and try Pro free

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.